HFE hemochromatosis: an overview about therapeutic recommendations

4Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hemochromatosis is currently characterized by the iron overload caused by hepcidin deficiency. Large advances in the knowledge on the hemochromatosis pathophysiology have occurred due to a better understanding of the protein of the iron metabolism, the genetic basis of hemochromatosis and of other iron overload diseases or conditions which can lead to this phenotype. In the present review, the main aims are to show updates on hemochromatosis and to report a practical set of therapeutic recommendations for the human factors engineering protein (HFE) hemochromatosis for the p.Cys282Tyr (C282Y/C282Y) homozygous genotype, elaborated by the Haemochromatosis International Taskforce.

Cite

CITATION STYLE

APA

Cancado, R. D., Alvarenga, A. M., & Santos, P. C. J. (2022). HFE hemochromatosis: an overview about therapeutic recommendations. Hematology, Transfusion and Cell Therapy, 44(1), 95–99. https://doi.org/10.1016/j.htct.2021.06.020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free